产品
编 号：F167827
分子式：C19H25NO3
分子量：315.41
分子式：C19H25NO3
分子量：315.41
产品类型
规格
价格
是否有货
结构图
CAS No: 145375-43-5
产品详情
生物活性：
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes.
体内研究：
Mitiglinide (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load.Animal Model:Pregnant Wistar rats (12 weeks)
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg
Administration:Oral administration
Result:Dose-dependently suppressed AUCglucose levels.
体外研究：
Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells.
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes.
体内研究：
Mitiglinide (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load.Animal Model:Pregnant Wistar rats (12 weeks)
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg
Administration:Oral administration
Result:Dose-dependently suppressed AUCglucose levels.
体外研究：
Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备